MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective ...

Christ Church Anglican, West Campus Annex, 3801 Louis J Rodriguez Drive, Burns Chapel at MSU Texas: Christ Church is a new, ...

Complementary biochemical and structural findings reveal molecular principles underlying substrate selectivity by a model hyaluronan synthase.

Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsJasper Van GrunsvenPeter Griffith - Executive ...

TEACHERS ACROSS OUR STATE, STATE VIOLENCE AND DISRUPTIVE BEHAVIOR IN THEIR CLASSROOMS IS GETTING HARDER TO HANDLE. AND THEY’RE ASKING LAWMAKERS FOR HELP. THE IOWA SENATE JUST PASSED TWO BILLS TO GIVE ...

Abstract: Troposcatter transmission loss prediction models are based mainly on ITU-R’s empirical models; however, the available troposcatter propagation models do not enable the real-time calculation ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after ...

Insmed Incorporated ( INSM) Leerink Global Healthcare Conference 2026 March 10, 2026 8:00 AM EDT Good morning. Welcome to this fireside chat with Insmed. I'm Joe Schwartz from the biopharma equity ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.-    ASC30 SQ depo ...

Peptilogics' PLG0206 is a first-in-class anti-biofilm drug candidate being studied in patients with prosthetic joint infection (PJI), the first of multiple potential medical device-related infections ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...